Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized Trial.

Mangesh A ThoratPauline M LeveyJ Louise JonesSarah E PinderNigel J Bundred Ian S Fentiman Jack M Cuzick

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

HER2 overexpression is associated with significantly increased risk of in situ recurrence and is also predictive of radiotherapy benefit, with greater reductions in in situ but not invasive recurrences in HER2-positive DCIS.

Keyphrases

poor prognosis
early stage
cell proliferation
radiation therapy
locally advanced
radiation induced
transcription factor
cross sectional
free survival
binding protein
long non coding rna
rectal cancer